HCP Contracting: Reducing Risk Across U.S. and Global Regulations
Contracting with healthcare professionals (HCPs) is a necessary part of life sciences commercial and medical activities, and these arrangements are among the most highly regulated
Lexi Harris
Revenue Management Is Breaking for Growing Pharma Companies
Legacy systems weren’t built to scale, and the cracks are showing For emerging and mid‑market pharmaceutical companies, growth is the goal. Growth is also the
Why Integration Matters in Clinical Trial Transparency: From Reactive Redaction to a Connected Workflow
In many life sciences organizations, clinical transparency is still handled as a last-minute process. Documents are exported, emailed, redacted in isolation, and stitched back together
From Risk Mitigation to Intelligence Engine: The Next Evolution Leveraging AI in Compliance Platforms
Artificial intelligence (AI) in life sciences will not deliver enterprise value unless it is grounded in compliant, governed, and transparent engagement with external stakeholders. That
Washington’s New 340B Reporting Law: What Manufacturers Need to Know
Washington State has enacted legislation that would require drug manufacturers to report detailed 340B sales and discount data at the state level beginning April 1,
CMS Open Payments Review & Dispute Period: Practical Tips for Manufacturers
Each year, the CMS Open Payments pre‑publication review and dispute period runs from April 1 through May 15. During this window, physicians and teaching hospitals
The Science of the Story: Why Modern Scientific Storytelling Is Medical Affairs’ Most Urgent Capability Gap
Imagine this: an MSL has prepared a comprehensive 100-slide scientific deck for a planned KOL exchange. They’ve mapped the narrative to the latest clinical data,
State Price Transparency Reporting: Why It’s No Longer a Peripheral Compliance Task
State Price Transparency Reporting (SPTR) has changed quietly, rapidly, and in ways that materially affect pharmaceutical manufacturers. What was once treated as an occasional filing obligation
State of Coaching in Pharma 2026 – What’s Working, What’s Not, and What’s Next
Coaching in pharma is no longer a “nice‑to‑have.” In 2026, it is a strategic, auditable, and measurable capability—or a growing operational risk. As
State of Coaching in Pharma 2026 – What’s Working. What’s Not. And What’s Next.
Coaching has become one of the most critical—and most scrutinized—capabilities in the pharmaceutical industry. As organizations face growing complexity, heightened compliance expectations, and pressure to
Contact us
Ready to Grow Your Business Compliantly?
We’re happy to answer any questions you may have and help you determine which of our solutions and services best fit your needs.
Why Medispend:
- Life Sciences Focused
- End-to-End Solutions
- Regulatory Expertise
- Enterprise Scalability
- Advanced Analytics
- Trusted Partnership
What happens next?
1
We will reach out to you and schedule a call at your convenience
2
We have a discovery meeting to discuss your current processes and tools
3
We prepare a proposal with solutions and services tailored to your unique needs